Predict your next investment

BenevolentAI company logo
Corporation
SOFTWARE (NON-INTERNET/MOBILE) | Healthcare Software
benevolent.com

See what CB Insights has to offer

Founded Year

2013

Stage

Incubator/Accelerator | Alive

Total Raised

$345.55M

Mosaic Score

+40 points in the past 30 days

What is a Mosaic Score?
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

About BenevolentAI

BenevolentAI creates and applies AI and machine learning to update the way medicines are discovered and developed. Benevolent integrates its technology into every step of the drug discovery process from hypothesis generation to late-stage clinical development.

BenevolentAI Headquarter Location

Maple Street, 4-8

London, England, W1T 5HD,

United Kingdom

+44 (0) 20 3096 0720

Latest BenevolentAI News

09:00 ET BenevolentAI appoints Dr John Orloff to its Board of Directors

Sep 9, 2021

Biopharmaceutical veteran Dr John Orloff joins the BenevolentAI Board as a Non-Executive Director as it scales the development of its leading AI-derived drug pipeline News provided by Share this article Share this article LONDON, Sept. 9, 2021 /PRNewswire/ -- BenevolentAI has deepened the drug discovery and development expertise on its Board with the appointment of Dr John Orloff as a Non-Executive Director. Dr Orloff joins the BenevolentAI Board as it advances plans to scale its AI platform, partnerships and drug portfolio. Dr. John Orloff (PRNewsfoto/BenevolentAI) "Technological advances have created a new category of companies that have dramatically changed the way we approach drug discovery research, introducing previously impossible speed, accuracy and scale to the process." Dr Orloff commented, "BenevolentAI is a rare company in this emerging sector, in that they  have demonstrated in silico, in vitro and clinical validation of their technology, and I believe its unique approach will change how the entire industry discovers and develops drugs." As a global R&D and business leader with 25 years of experience in the biopharma industry, Dr Orloff will bring invaluable expertise across research, drug discovery, clinical development, medical affairs, health economics, and regulatory affairs to BenevolentAI's experienced Board of Directors. He joins Benevolent from Alexion, where he served as Executive Vice President and Global Head of R&D and, over three years, led the expansion of the development pipeline from 3 to 30 programs, spanning over 80 clinical trials from Phase 1 to Phase 4 . Previously, he was Global Head of R&D and Chief Scientific Officer at Baxalta, followed by the roles of Executive Vice President and Head of R&D at Novelion. He also held executive R&D roles at Merck Serono and Novartis. Dr Francios Nader, Chairman of BenevolentAI, commented; "Dr John Orloff adds invaluable scientific leadership expertise in preclinical research and clinical development to BenevolentAI's Board, and will be a guiding force as the company continues to drive innovation and uncover new treatments with a higher likelihood of clinical success." Joanna Shields, CEO and Board Director of BenevolentAI, commented, "As the Benevolent platform scales and we accelerate the development of our internal pipeline of novel drugs, Dr. John Orloff brings an impressive track record in R&D and commercialisation to our Board and we warmly welcome John to the team." Dr Orloff received his A.B. from Dartmouth College and earned his MD from the University of Vermont College of Medicine, completing his medical training at the University of Pittsburgh Medical Center and Yale University School of Medicine. Media inquiries About BenevolentAI BenevolentAI combines advanced AI and machine learning with cutting edge science to decipher complex disease biology, generate novel insights and discover more effective medicines. Our unique computational R&D platform spans every step of the drug discovery process, powering an in-house pipeline of 25+ drug programmes from early discovery towards clinical phases. With several successful collaborations with leading pharmaceutical organisations, we are also the only AI-drug discovery company with a clinically validated approach, discovering a leading repurposed drug candidate for COVID-19. BenevolentAI is headquartered in London with a research facility in Cambridge (UK) and a further office in New York, with a team of over 300 world-leading scientists and technologists progressing its mission to reinvent drug discovery and advance life-changing drugs through to the clinic. SOURCE BenevolentAI

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing BenevolentAI

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned BenevolentAI in 3 CB Insights research briefs, most recently on Jun 24, 2021.

Expert Collections containing BenevolentAI

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

BenevolentAI is included in 6 Expert Collections, including Unicorns- Billion Dollar Startups.

U

Unicorns- Billion Dollar Startups

827 items

A

Artificial Intelligence ( AI ) in Healthcare

826 items

These healthcare startups are using AI to discover new drugs, remotely monitor patients, securely transfer patient data, and more.

H

Healthcare Horizons

27 items

Cutting-edge developments in healthcare, and the startups behind them, that are just beginning to impact the world. This collection includes companies covered in the Healthcare Horizons briefing and accompanying report.

C

Clinical Trials Tech

424 items

Companies developing products and services to streamline drug R&D, from drug discovery, pre-clinical testing, and clinical trials.

F

Future of Pharma R&D

62 items

A

Artificial Intelligence

7,362 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

BenevolentAI Patents

BenevolentAI has filed 19 patents.

The 3 most popular patent topics include:

  • Machine learning
  • Bioinformatics
  • Biological databases
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/17/2019

6/22/2021

Clusters of differentiation, Cytokines, Inflammations, Transcription factors, Proteins

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

7/17/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

6/22/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Clusters of differentiation, Cytokines, Inflammations, Transcription factors, Proteins

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

BenevolentAI Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

BenevolentAI Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.